scholarly journals Circulating Insulin-Like Growth Factor-1 Level and Ovarian Cancer Risk

2016 ◽  
Vol 38 (2) ◽  
pp. 589-597 ◽  
Author(s):  
Yiyang Li ◽  
Yang Li ◽  
Jialing Zhang ◽  
Changjun Zheng ◽  
He Zhu ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Growth Factor ◽  
Cancer Risk ◽  
Confidence Interval ◽  
Odds Ratio ◽  
Meta Analysis ◽  
Epidemiological Studies ◽  
Ovarian Cancer Risk ◽  
Insulin Like Growth Factor ◽  
Summary Odds Ratio

Background/Aims: Insulin-like growth factor-1 (IGF-1) has an important role in cells' proliferation, differentiation and apoptosis, and it may be involved in carcinogenesis. Several epidemiological studies assessed the association between circulating IGF-1 level and ovarian cancer risk, but there was still no conclusive finding. Methods: A meta-analysis of published studies was performed to assess the association between circulating IGF-1 level and ovarian cancer risk. The summary odds ratio (OR) with 95% confidence interval (95%CI) was calculated through meta-analysis to evaluate the strength of the association. Results: Five eligible studies were included into the meta-analysis, which involved a total of 2,028 cases of ovarian cancer and 4,625 controls. Meta-analysis of total 5 studies showed that high circulating IGF-1 level was correlated with decreased risk of ovarian cancer (OR = 0.84, 95%CI 0.74-0.97, P = 0.013). After adjusting for heterogeneity, high circulating IGF-1 level was still correlated with decreased risk of ovarian cancer (OR = 0.83, 95%CI 0.72-0.95, P = 0.007). Subgroup analysis by age showed that circulating IGF-1 level was not correlated with ovarian cancer risk in women both less than 55 years and more than 55 years. However, after adjusting for heterogeneity, high circulating IGF-1 level was correlated with decreased ovarian cancer risk in women less than 55 years (OR = 0.82, 95%CI 0.72-0.94, P = 0.004). Conclusion: Our meta-analysis suggests that high circulating IGF-1 level may be correlated with decreased ovarian cancer risk, especially in women less than 55 years. More studies are needed to further assess the association between circulating IGF-1 level and ovarian cancer risk in the future.

scholarly journals Effect of Basal Metabolic Rate on Cancer: A Mendelian Randomization Study

2021 ◽  
Vol 12 ◽  
Author(s):  
Jack C. M. Ng ◽  
C. Mary Schooling
Keyword(s):  
Growth Factor ◽  
Cancer Risk ◽  
Confidence Interval ◽  
Metabolic Rate ◽  
Basal Metabolic Rate ◽  
Odds Ratio ◽  
Mendelian Randomization ◽  
Causal Effect ◽  
Sensitivity Analyses ◽  
Insulin Like Growth Factor

Background: Basal metabolic rate is associated with cancer, but these observations are open to confounding. Limited evidence from Mendelian randomization studies exists, with inconclusive results. Moreover, whether basal metabolic rate has a similar role in cancer for men and women independent of insulin-like growth factor 1 increasing cancer risk has not been investigated.Methods: We conducted a two-sample Mendelian randomization study using summary data from the UK Biobank to estimate the causal effect of basal metabolic rate on cancer. Overall and sex-specific analysis and multiple sensitivity analyses were performed including multivariable Mendelian randomization to control for insulin-like growth factor 1.Results: We obtained 782 genetic variants strongly (p-value < 5 × 10–8) and independently (r2 < 0.01) predicting basal metabolic rate. Genetically predicted higher basal metabolic rate was associated with an increase in cancer risk overall (odds ratio, 1.06; 95% confidence interval, 1.02–1.10) with similar estimates by sex (odds ratio for men, 1.07; 95% confidence interval, 1.002–1.14; odds ratio for women, 1.06; 95% confidence interval, 0.995–1.12). Sensitivity analyses including adjustment for insulin-like growth factor 1 showed directionally consistent results.Conclusion: Higher basal metabolic rate might increase cancer risk. Basal metabolic rate as a potential modifiable target of cancer prevention warrants further study.

Insulin growth factor (IGF) 1, IGF-binding proteins and ovarian cancer risk: A systematic review and meta-analysis

Maturitas ◽  
2016 ◽  
Vol 94 ◽  
pp. 22-29 ◽  
Author(s):  
Ximena Gianuzzi ◽  
Gabriela Palma-Ardiles ◽  
Wendy Hernandez-Fernandez ◽  
Vinay Pasupuleti ◽  
Adrian V. Hernandez ◽  
...  
Keyword(s):  
Systematic Review ◽  
Ovarian Cancer ◽  
Growth Factor ◽  
Cancer Risk ◽  
Binding Proteins ◽  
Meta Analysis ◽  
Ovarian Cancer Risk ◽  
Igf Binding Proteins ◽  
Insulin Growth Factor ◽  
Igf Binding

A Method for Meta-Analysis of Epidemiological Studies

1988 ◽  
Vol 22 (10) ◽  
pp. 813-824 ◽  
Author(s):  
Thomas R. Einarson ◽  
J. Steven Leeder ◽  
Gideon Koren
Keyword(s):  
Confidence Interval ◽  
Odds Ratio ◽  
Meta Analysis ◽  
A Priori ◽  
Epidemiological Studies ◽  
Percent Confidence Interval ◽  
Case Control Studies ◽  
Chi Square ◽  
The Impact ◽  
Summary Odds Ratio

This article presents a stepwise approach for conducting a meta-analysis of epidemiological studies based on proposed guidelines. This systematic method is recommended for practitioners evaluating epidemiological studies in the literature to arrive at an overall quantitative estimate of the impact of a treatment. Bendectin is used as an illustrative example. Meta-analysts should establish a priori the purpose of the analysis and a complete protocol. This protocol should be adhered to, and all steps performed should be recorded in detail. To aid in developing such a protocol, we present methods the researcher can use to perform each of 22 steps in six major areas. The illustrative meta-analysis confirmed previous traditional narrative literature reviews that Bendectin is not related to teratogenic outcomes in humans. The overall summary odds ratio was 1.01 (χ2 = 0.05, p = 0.815) with a 95 percent confidence interval of 0.66–1.55. When the studies were separated according to study type, the summary odds ratio for cohort studies was 0.95 with a 95 percent confidence interval of 0.62–1.45. For case-control studies, the summary odds ratio was 1.27 with a 95 percent confidence interval of 0.83–1.94. The corresponding chi-square values were not statistically significant at the p = 0.05 level.

scholarly journals Breastfeeding and Ovarian Cancer Risk: a Systematic Review and Meta-analysis of 40 Epidemiological Studies

2014 ◽  
Vol 15 (12) ◽  
pp. 4829-4837 ◽  
Author(s):  
Da-Peng Li ◽  
Chen Du ◽  
Zuo-Ming Zhang ◽  
Guang-Xiao Li ◽  
Zhi-Fu Yu ◽  
...  
Keyword(s):  
Systematic Review ◽  
Ovarian Cancer ◽  
Cancer Risk ◽  
Meta Analysis ◽  
Epidemiological Studies ◽  
Ovarian Cancer Risk

Glutathione S-transferase M1, T1, and P1 Polymorphisms and Ovarian Cancer Risk: A Meta-Analysis

2010 ◽  
Vol 20 (5) ◽  
pp. 732-737 ◽  
Author(s):  
Konstantinos P. Economopoulos ◽  
Theodoros N. Sergentanis ◽  
Nikos F. Vlahos
Keyword(s):  
Ovarian Cancer ◽  
Cancer Risk ◽  
Confidence Interval ◽  
Random Effects ◽  
Fixed Effects ◽  
Meta Analysis ◽  
Ovarian Cancer Risk ◽  
Case Control Studies ◽  
Increased Risk ◽  
Gstp1 Ile105val

Introduction:Cytosolic glutathione S-transferase (GST) comprises multiple isoenzymes that catalyze reactions between glutathione and lipophilic compounds with electrophilic centers, resulting in the neutralization of toxic compounds, xenobiotics, and products of oxidative stress. Several studies have examined whether GST polymorphisms (GSTM1 null/present genotype, GSTT1 null/present genotype, and GSTP1 Ile105Val) represent risk factors for ovarian cancer, as they all may denote reduced enzyme activity. This meta-analysis aimed to examine the associations between the aforementioned polymorphisms and ovarian cancer risk.Methods:The MEDLINE database was searched up to September 2009 using the appropriate terms. Case-control studies with no mutually overlapping populations were selected. Pooled odds ratios (ORs) were appropriately derived from fixed-effects or random-effects models. Meta-regression with publication year was also performed.Results:Eight studies regarding GSTM1 null polymorphism status (2357 cases and 3044 controls), 6 studies concerning GSTT1 null polymorphism (1923 cases and 2759 controls), and 3 studies on GSTP1 Ile105Val were included in the meta-analysis. The GSTM1 null genotype was not associated with an increased risk for ovarian cancer (pooled OR, 1.031; 95% confidence interval, 0.867-1.226; random effects). The GSTT1 null genotype was not associated with an increased ovarian cancer risk (pooled OR, 0.934; 95% confidence interval, 0.804-1.086; random effects); similarly, no significant associations were demonstrated for GSTP1 Ile105Val.Conclusions:The examined GSTM1, GSTT1, and GSTP1 genotype polymorphisms do not seem to confer any additional risk for ovarian cancer. Given that the studies included in this meta-analysis involve mainly white populations, these results cannot be extrapolated on other populations, and additional data are needed for future race-specific analyses.

scholarly journals Genetic variation in insulin-like growth factor 2 may play a role in ovarian cancer risk

2011 ◽  
Vol 20 (11) ◽  
pp. 2263-2272 ◽  
Author(s):  
Celeste Leigh Pearce ◽  
Jennifer A. Doherty ◽  
David J. Van Den Berg ◽  
Kirsten Moysich ◽  
Chris Hsu ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Genetic Variation ◽  
Growth Factor ◽  
Cancer Risk ◽  
Ovarian Cancer Risk ◽  
Insulin Like Growth Factor
Sign in / Sign up

Export Citation Format

Share Document